congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
T-DXd
ESMO Asia 2023 | December 1-3, 2023
A multicenter randomized open-label phase 2 study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study
Mini-Oral
Dato-DXd
ESMO Asia 2023 | December 1-3, 2023
Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase 3 study TROPION-Lung01
Mini-Oral
T-DXd
ESMO Asia 2023 | December 1-3, 2023
Trastuzumab deruxtecan for pretreated patients with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 study
Mini-Oral
T-DXd
ESMO Asia 2023 | December 1-3, 2023
Trastuzumab deruxtecan in Asian patients with human epidermal growth factor receptor 2 (HER2; ERBB2)-mutant metastatic non-small cell lung cancer: Subgroup analysis of DESTINY-Lung02
Poster
T-DXd
ESMO Asia 2023 | December 1-3, 2023
Trastuzumab deruxtecan in Chinese patients with previously treated HER2-positive locally advanced/metastatic gastric cancer or gastroesophageal junction adenocarcinoma: Primary efficacy and safety from the phase 2 single-arm DESTINY-Gastric06 trial
Poster
Dato-DXd
ESMO Asia 2023 | December 1-3, 2023
TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations
Mini-Oral
Dato-DXd
ESMO Asia 2023 | December 1-3, 2023
TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer with actionable genomic alterations